Drugs / AK-106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01285752 | Feb 2011 → Jan 2012 | rheumatoid arthritis | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00902369 | May → Oct 2009 | rheumatoid arthritis | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK-106 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297481 ↗ |
| Known as | AK106-001616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00902369 ↗ |
| Action | Inhibit | “AK106-001616, a novel cytosolic phospholipase A2 inhibitor” PMID 25579091 ↗ Jan 2015 |
| Modality | Small molecule | — CHEMBL4297481 ↗ |